Peramivir clearance in continuous renal replacement therapy

Hemodialysis International

Volumn 14, Issue 3, 2010, Pages 339-340

  Thomas, Bernadette ^a   Hollister, Alan S ^b   Muczynski, Kimberly A ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR;

ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ADULT; CASE REPORT; CONTINUOUS RENAL REPLACEMENT THERAPY; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DYSPNEA; FEMALE; FEVER; HEMODIALYSIS; HUMAN; INFLUENZA A (H1N1); INTUBATION; LETTER; LUNG EDEMA; LUNG INFILTRATE; MALE; MAXIMUM PLASMA CONCENTRATION; OXYGEN THERAPY; POSITIVE END EXPIRATORY PRESSURE; RESPIRATORY FAILURE; SLOW LOW EFFICIENCY HEMODIALYSIS;

ADULT; ANTIVIRAL AGENTS; CYCLOPENTANES; ENZYME INHIBITORS; FEMALE; GUANIDINES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; NEURAMINIDASE; RENAL DIALYSIS;

EID: 77955021268     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2010.00451.x     Document Type: Letter

References (1)

1. http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf, Peramivir Emergency Use Authorization. Available from, (accessed date: November 19, 2009)